CSF2 and COVID-19: GM‐CSF antibodies, such as mavrilimumab and lenzilumab, are indicated for autoimmune diseases and inflammatory diseases, such as RA or giant cell arteritis; these are now under investigation as potential therapies for COVID‐19.